LOGO.png
Hillstream BioPharma R&D Day Highlights Ferroptosis, the Non-Genetic Novel, Emerging Mechanism of Action, Targeting Drug Resistant and Devastating Cancers
02 mars 2022 08h37 HE | Hillstream BioPharma Inc.
HSB-1216’s active moiety in clinical pilot study produced a 71% response rate in TNBC and epithelial carcinomasHSB-1216 was recently granted Orphan Drug Designation to treat Uveal Melanoma by the...
Beroni Logo @ Dec 2019.png
Beroni Initiates Manufacture of its Novel, Potential Anti-Cancer Drug PENAO
18 août 2021 08h30 HE | Beroni Group Limited
NEW YORK and SYDNEY, Australia, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni”), an Australia-based diversified biopharmaceutical enterprise, announced that PENAO...
Beroni Logo @ Dec 2019.png
Beroni Acquires Majority Interest in PENAO, an Anti-Cancer Drug Development Company
03 févr. 2021 08h30 HE | Beroni Group Limited
NEW YORK and SYDNEY, Australia, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni”), an Australia-based diversified biopharmaceutical enterprise today announces...
Beroni Logo @ Dec 2019.png
Beroni Group Launches a New Probiotics Health Product in China
10 nov. 2020 08h30 HE | Beroni Group Limited
NEW YORK and SYDNEY, Australia, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni” or the “Company”), an Australia-based diversified biopharmaceutical enterprise...